ZiJun Liao^*†, Qi Zheng^†, Ting Wei^‡, YanBing Zhang^†, JieQun Ma^†, Zheng Zhao^§, HaiFeng Sun^§, KeJun Nan^*

Oncology Research, Vol.28, No.2, pp. 147-159, 2020, DOI:10.3727/096504019X15732109856009

Abstract MicroRNAs (miRNAs) play crucial roles in tumorigenesis and tumor progression. miR-561 has been reported to be downregulated in gastric cancer and affects cancer cell proliferation and metastasis. However, the role and underlying molecular mechanism of miR-561 in human non-small cell lung cancer (NSCLC) remain unknown and need to be further elucidated. In this study, we discovered that miR-561 expression was downregulated in human NSCLC tissues and cell lines. The overexpression of miR-561 inhibited NSCLC cell proliferation and cell cycle G1 /S transition and induced apoptosis. The inhibition of miR-561 facilitated cell proliferation and G1 /S… More >

Jianping Xu, Xiaoyan Liu, Sheng Yang, Yuankai Shi

Oncology Research, Vol.28, No.2, pp. 127-133, 2020, DOI:10.3727/096504019X15707896762251

Abstract Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in China, exerts antiangiogenic and antineoplastic function through selectively binding and inhibiting vascular endothelial growth factor receptor 2 (VEGFR-2). In this study, we aimed to explore the efficacy and safety profile of apatinib monotherapy, or combined with chemotherapy or endothelial growth factor receptor (EGFR)-TKI in heavily pretreated non-small cell lung cancer (NSCLC) patients with brain metastases. We performed a retrospective analysis for relapsed NSCLC patients with brain metastases from our institute, who received apatinib (250 mg or 500 mg p.o. qd) monotherapy, or… More >

Xiuhua Weng^*1, Shaohong Luo^*1, Shen Lin^*, Lixian Zhong^†, Meiyue Li^*, Rao Xin^*, Pinfang Huang^*, Xiongwei Xu^*

Oncology Research, Vol.28, No.2, pp. 117-125, 2020, DOI:10.3727/096504019X15707883083132

Abstract To evaluate the cost–utility of pembrolizumab versus chemotherapy as the first-line setting for metastatic nonsmall cell lung cancer (NSCLC) from the US health care system perspective, a Markov model was developed to compare the lifetime cost and effectiveness of pembrolizumab versus chemotherapy for untreated metastatic NSCLC, based on the clinical data derived from phase III randomized controlled trial (KEYNOTE- 042; ClinicalTrials.gov; NCT02220894). Weibull distribution was fitted to simulate the parametric survival functions. Drug costs were collected from official websites, and utility values were obtained from published literature. Total costs, quality-adjusted life years (QALYs), and incremental… More >

Stefania Nobili^*, Daniele Lavacchi^†, Gabriele Perrone^*, Giulio Vicini^†, Renato Tassi^‡1, Ida Landini^*, AnnaMaria Grosso^§, Giandomenico Roviello^*¶, Roberto Mazzanti^‡, Carmine Santomaggio^¶2, Enrico Mini^*¶

Oncology Research, Vol.28, No.3, pp. 237-248, 2020, DOI:10.3727/096504019X15755437099308

Abstract The use of vinorelbine as a single agent or in combination regimens in non-small cell lung cancer (NSCLC) is associated with satisfactory clinical activity. However, the role of vinorelbine-based chemotherapy in chemonaive locally advanced unresectable or metastatic NSCLC patients, according to real-world treatment patterns, has still not been widely explored. Eighty-one patients treated at a single institution were retrospectively analyzed. Thirty-seven received standard first-line single-agent vinorelbine, and 44 received vinorelbine plus platinum drugs, based on physician’s choice; 61.7% were older than 70 years, and 60.5% were affected by 2 comorbidities. Sixty-three patients were evaluable for… More >

Yanhui Li^*†, Su Dong^*†, Arya Tamaskar^†, Heather Wang^†, Jing Zhao^†, Haichun Ma^*, Yutong Zhao^†

Oncology Research, Vol.28, No.5, pp. 497-507, 2020, DOI:10.3727/096504020X15929939001042

Abstract Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and accounts for 85% of all lung carcinomas. The hepatocyte growth factor receptor (c-Met) has been considered as a potential therapeutic target for NSCLC. Proteasome inhibition induces cell apoptosis and has been used as a novel therapeutic approach for treating diseases including NSCLC; however, the effects of different proteasome inhibitors on NSCLC have not been fully investigated. The aim of this study is to determine a precise strategy for treating NSCLC by targeting c-Met using different proteasome inhibitors. Three proteasome inhibitors, bortezomib,… More >

Guojie Chen^*1, Kai Wang^*1, Guoshu Li^†1, Leidong Wang^‡, Yangyang Xiao^§, Bo Chen^¶

Oncology Research, Vol.28, No.9, pp. 945-959, 2020, DOI:10.3727/096504021X16328213967104

Abstract Long noncoding RNA LAMTOR5 antisense RNA 1 (LAMTOR5-AS1) has been certified as a risk predictor and diagnostic biomarker of prostate cancer. However, the expression and exact roles of LAMTOR5-AS1 in nonsmall cell lung cancer (NSCLC) remain unclear. Thus, we measured LAMTOR5-AS1 expression in NSCLC and gauged its clinical value. The detailed roles and downstream working mechanism of LAMTOR5-AS1 in NSCLC were comprehensively unraveled. qRT-PCR was applied to measure gene expression. Functionally, utilizing small interfering RNA, LAMTOR5-AS1 was ablated, and the functional alterations were addressed by means of different experiments. The targeting activities between LAMTOR5-AS1 and… More >

Ziyi Wang^*, Xinyu Zhang^*, Xuedong Zhang^†, Xuedong Jiang^‡, Wenya Li^*

Oncology Research, Vol.28, No.9, pp. 913-927, 2020, DOI:10.3727/096504021X16310057751016

Abstract Long intergenic nonprotein-coding RNA 1703 (LINC01703) has diagnostic significance in lung adenocarcinoma. However, its specific roles in non-small cell lung cancer (NSCLC) and downstream mechanisms have not been investigated. In the current study, we characterized the role of LINC01703 in NSCLC malignancy and elucidated its detailed mechanism of action. LINC01703 expression was measured by qRT-PCR. The regulatory effects of LINC01703 on the malignancy of NSCLC cells were assessed by multiple functional experiments. The targeted interaction was confirmed by RNA immunoprecipitation and luciferase reporter assays. Herein, overexpression of LINC01703 in NSCLC was indicated in the TCGA… More >

Xiangbin Tan^*1, Zefei Liao^†1, Shuangyou Zou^*, Liangyun Ma^†, Aimin Wang^*

Oncology Research, Vol.28, No.1, pp. 3-11, 2020, DOI:10.3727/096504019X15509383469698

Abstract Vasohibin2 (VASH2), a proangiogenic factor, has been demonstrated to play an oncogenic role in some common human cancers. However, the detailed function of VASH2 in non-small cell lung cancer (NSCLC) has not previously been studied. In this study, we found that VASH2 was significantly upregulated in NSCLC tissues and cell lines, and its increased expression was associated with NSCLC progression and poor prognosis of patients. Knockdown of VASH2 markedly inhibited cell proliferation and P-glycoprotein expression in NSCLC cells. Overexpression of VASH2 enhanced cell proliferation, P-glycoprotein expression, as well as doxorubicin resistance in NSCLC cells. Moreover,… More >

Nan Geng¹, Wenxia Hu¹, Zhikun Liu², Jingwei Su², Wenyu Sun³, Shaonan Xie⁴, Cuimin Ding^1,*

Oncologie, Vol.22, No.4, pp. 245-254, 2020, DOI:10.32604/oncologie.2020.014125

Abstract Objective: This study was set out to inquire into the expression and clinical significance of lncRNA activated by transforming growth factor β (LncRNA-ATB) and in cancer tissues of patients with non-small cell lung cancer (NSCLC). Methods: LncRNA-ATB in cancer tissues and adjacent tissues of 89 NSCLC patients was detected by quantitative real-time polymerase chain reaction (qRT-PCR), and its clinical diagnostic value in NSCLC was determined by receiver operating characteristic (ROC) curves. Based on the median expression of LncRNAATB in NSCLC tissues, 89 patients were allocated into high- and low-expression groups. The 3-year survival rate was… More >

Binbin QIAN¹, Xiaoduo LIU², Xiaolin GU¹, Lu YANG³, Dake CHEN^1,*

BIOCELL, Vol.44, No.1, pp. 19-26, 2020, DOI:10.32604/biocell.2020.07859 - 01 March 2020

Abstract Prolylcarboxypeptidase (PRCP) belongs to the S28 family of proteases, which is also a dipeptidyl peptidase. In this study, we demonstrate the expression pattern of PRCP in Non-small cell lung cancer (NSCLC). We found that the repression of PRCP expression by small interfering RNA successfully inhibited cell proliferation, migration, and invasion. Further, we explored the involvement of PRCP in the regulation of epithelial-mesenchymal transition (EMT). The epithelial marker E-cadherin was significantly increased, meanwhile mesenchymal markers MUC1, vimentin, and SNAIL were markedly decreased in PRCP knockdown cells. Moreover, the downregulation of PRCP in the NSCLC cells induced More >